Table 1.
Patient and Healthy Donor Characteristics.
| Characteristics | Ipilimumab 10mg/kg | Ipilimumab 3mg/kg | Healthy Donors* |
|---|---|---|---|
| Number of Patients | 28 | 40 | 20 |
| Median Age (range) | 62 (34–83) | 60 (34–80) | 38(26–58) |
| Sex (%) | |||
| Male | 17(61) | 29 (73) | 10 (50) |
| Female | 11(39) | 11(27) | 7 (35) |
| Stage of disease (%) | |||
| III (unresectable) | 0 | 1 | - |
| M1a | 3 | 0 | - |
| M1b | 4 | 5 | - |
| M1c | 21 | 34 | - |
| Median number of prior therapies (range) | 1 (0–3) | 1 (0–5) | - |
| Median LDH (range) | 209 (113–968) | 211(117–816) | - |
| ≥Upper limit of normal (% of available LDH) | 13 (46) | 28(70) | - |
| <Upper limit of normal (% of available LDH) | 15 (54) | 12(30) | - |
| MDSC Frequency %HLA-DR low/− in Lin"CD14+CDllb+ (range)** | 11.4 (3.9–24.5) | 11.2(5.8–20.9) | 10.3(6.4–14.3) |
| ≥ 14.9 (%) | 7(25) | 7(18) | 0(0) |
| < 14.9 (%) | 21(75) | 33 (82) | 20 (100) |
| Median baseline ALC (range) | 1250 (500–5100) | 1100(600–8100) | - |
| ≥ 1000/µl (%) | 19(68) | 25 (63) | - |
| < 1000/µl (%) | 9(32) | 15 (37) | - |
*
Data for anonymously donated blood bank samples is unavailable
*
Baseline values